Evidence Feed - LARVOL VERI

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 2d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days osimertinib Sensitive : A1 J Clin Oncol - 2 days - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days (New B) osimertinib Sensitive : A1 J Clin Oncol - 2d	osimertinib Sensitive: A1 - Approval J Clin Oncol - 2 days osimertinib Sensitive : A1 J Clin Oncol - 2 days - (New B)
EML4-ALK fusion	Neuroendocrine Tumor	EML4-ALK fusion	Neuroendocrine Tumor	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 2 days (New C4) alectinib Sensitive : C4 Ann Transl Med - 2d	alectinib Sensitive: C4 – Case Studies Ann Transl Med - 2 days alectinib Sensitive : C4 Ann Transl Med - 2 days - (New C4)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval BMC Cancer - 3 days (New C3) palbociclib Sensitive : A1 BMC Cancer - 3d	palbociclib Sensitive: A1 - Approval BMC Cancer - 3 days palbociclib Sensitive : A1 BMC Cancer - 3 days - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days (New C3) BSI 201 Sensitive : C3 Oncologist - 3d	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days BSI 201 Sensitive : C3 Oncologist - 3 days - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days (New C3) BSI 201 Sensitive : C3 Oncologist - 3d	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days BSI 201 Sensitive : C3 Oncologist - 3 days - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days (New C3) TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5d	TPX-0005 Sensitive: B - Late Trials IASLC-TTLC 2023 - 5 days TPX-0005 Sensitive : B IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	BI 1810631 Sensitive: C2 – Inclusion Criteria IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C2 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C2 – Inclusion Criteria IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C2 IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 5d	TPX-0005 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days TPX-0005 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 5 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 5 days - (New C3)
Chr del(9p) + PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	Chr del(9p) + PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + PTEN mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + BRCA1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + ARID1A mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + NF1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation + RB1 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5d	EGFR inhibitor Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days EGFR inhibitor Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
KEAP1 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
STK11 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 deletion + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days (New C3) Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5d	Immunotherapy Resistant: C3 – Early Trials IASLC-TTLC 2023 - 5 days Immunotherapy Resistant : C3 IASLC-TTLC 2023 - 5 days - (New C3)
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 5d	amivantamab-vmjw Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days amivantamab-vmjw Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
MET F1200I	Lung Adenocarcinoma	MET F1200I	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y	Lung Adenocarcinoma	MET H1094Y	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 5d	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 5 days pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 5 days - (New C4)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval Bayer Press Release - 6 days (New B) darolutamide Sensitive : A1 Bayer Press Release - 6d	darolutamide Sensitive: A1 - Approval Bayer Press Release - 6 days darolutamide Sensitive : A1 Bayer Press Release - 6 days - (New B)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval FDA - 6 days (New A1) pirtobrutinib Sensitive : A1 FDA - 6d	pirtobrutinib Sensitive: A1 - Approval FDA - 6 days pirtobrutinib Sensitive : A1 FDA - 6 days - (New A1)
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 6 days (New B) temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 6d	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 6 days temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 6 days - (New B)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval FDA - 6 days (New A1) elacestrant Sensitive : A1 FDA - 6d	elacestrant Sensitive: A1 - Approval FDA - 6 days elacestrant Sensitive : A1 FDA - 6 days - (New A1)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	capecitabine Sensitive: A2 - Guideline NCCN - 6 days (New A2) capecitabine Sensitive : A2 NCCN - 6d	capecitabine Sensitive: A2 - Guideline NCCN - 6 days capecitabine Sensitive : A2 NCCN - 6 days - (New A2)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline NCCN - 6 days (New A2) pembrolizumab Sensitive : A2 NCCN - 6d	pembrolizumab Sensitive: A2 - Guideline NCCN - 6 days pembrolizumab Sensitive : A2 NCCN - 6 days - (New A2)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 6 days (New D) dasatinib + lapatinib Sensitive : D PLoS One - 6d	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 6 days dasatinib + lapatinib Sensitive : D PLoS One - 6 days - (New D)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 1 week (New A1) pembrolizumab Sensitive : A1 FDA - 1wk	pembrolizumab Sensitive: A1 - Approval FDA - 1 week pembrolizumab Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week (New A2) lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1wk	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week (New A2) mosunetuzumab Sensitive : A1 NCCN - 1wk	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week mosunetuzumab Sensitive : A1 NCCN - 1 week - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) acalabrutinib Sensitive : A2 NCCN - 1wk	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week acalabrutinib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week (New A2) tazemetostat Sensitive : A2 NCCN - 1wk	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week tazemetostat Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 1wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week trastuzumab + tucatinib Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 overexpression	Endometrial Cancer	HER-2 overexpression	Endometrial Cancer	DB-1303 Sensitive: B - Late Trials PRNewswire - 1 week (New B) DB-1303 Sensitive : B PRNewswire - 1wk	DB-1303 Sensitive: B - Late Trials PRNewswire - 1 week DB-1303 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week (New B) pembrolizumab Sensitive : B Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : B Merck (MSD) Press Release - 1 week - (New B)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week (New C3) olaparib Sensitive : A1 Anticancer Res - 1wk	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week olaparib Sensitive : A1 Anticancer Res - 1 week - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week (New C3) olaparib Sensitive : A1 Anticancer Res - 1wk	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week olaparib Sensitive : A1 Anticancer Res - 1 week - (New C3)
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 week (New A1) fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 1 week - (New A1)
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	abemaciclib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 1 week (New C3) abemaciclib Sensitive : C2 J Clin Oncol - 1wk	abemaciclib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 1 week abemaciclib Sensitive : C2 J Clin Oncol - 1 week - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week (New C3) trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1wk	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1 week - (New C3)
ALK fusion	Lung Adenocarcinoma	ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C2 – Inclusion Criteria Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C2 Anticancer Drugs - 1wk	alectinib Sensitive: C2 – Inclusion Criteria Anticancer Drugs - 1 week alectinib Sensitive : C2 Anticancer Drugs - 1 week - (New C4)
ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	ROS1 fusion + KRAS G12C	Non Small Cell Lung Cancer	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week (New C4) entrectinib Resistant : C4 NPJ Precis Oncol - 1wk	entrectinib Resistant: C4 – Case Studies NPJ Precis Oncol - 1 week entrectinib Resistant : C4 NPJ Precis Oncol - 1 week - (New C4)
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C4 Anticancer Drugs - 1wk	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week alectinib Sensitive : C4 Anticancer Drugs - 1 week - (New C4)
RET fusion + TP53 mutation	HER2 Positive Breast Cancer	RET fusion + TP53 mutation	HER2 Positive Breast Cancer	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week (New C4) pyrotinib Resistant : C4 Anticancer Drugs - 1wk	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week pyrotinib Resistant : C4 Anticancer Drugs - 1 week - (New C4)
TMB-H + PD-L1 expression	Lung Cancer	TMB-H + PD-L1 expression	Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 1 week (New C4) pembrolizumab Sensitive : C4 Medicine (Baltimore) - 1wk	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 1 week pembrolizumab Sensitive : C4 Medicine (Baltimore) - 1 week - (New C4)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) crizotinib Sensitive : A1 Cancer Manag Res - 2wk	crizotinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks crizotinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks (New B) bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2wk	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2 weeks - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) sorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks sorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) fruquintinib Sensitive : A1 ASCO-GI 2023 - 2wk	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks fruquintinib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks (New A1) serplulimab Sensitive : A1 Henlius Press Release - 2wk	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks serplulimab Sensitive : A1 Henlius Press Release - 2 weeks - (New A1)
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks (New A1) penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2wk	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2 weeks - (New A1)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks (New C3) cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2wk	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks (New C3) CDK6 inhibitor Sensitive : B Endokrynol Pol - 2wk	CDK6 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks CDK6 inhibitor Sensitive : B Endokrynol Pol - 2 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks (New C3) CDK4 inhibitor Sensitive : B Endokrynol Pol - 2wk	CDK4 inhibitor Sensitive: B - Late Trials Endokrynol Pol - 2 weeks CDK4 inhibitor Sensitive : B Endokrynol Pol - 2 weeks - (New C3)
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks (New B) toripalimab Sensitive : B BioSpace - 2wk	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks toripalimab Sensitive : B BioSpace - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 2wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) IMAB362 Sensitive : B ASCO-GI 2023 - 2wk	IMAB362 Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks IMAB362 Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks (New B) osimertinib Sensitive : A1 Future Oncol - 2wk	osimertinib Sensitive: A1 - Approval Future Oncol - 2 weeks osimertinib Sensitive : A1 Future Oncol - 2 weeks - (New B)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) alectinib Sensitive : A1 Cancer Manag Res - 2wk	alectinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks alectinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval ASCO.org - 2 weeks (New A2) pembrolizumab Sensitive : A1 ASCO.org - 2wk	pembrolizumab Sensitive: A1 - Approval ASCO.org - 2 weeks pembrolizumab Sensitive : A1 ASCO.org - 2 weeks - (New A2)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval NCCN - 2 weeks (New A2) olutasidenib Sensitive : A1 NCCN - 2wk	olutasidenib Sensitive: A1 - Approval NCCN - 2 weeks olutasidenib Sensitive : A1 NCCN - 2 weeks - (New A2)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks (New C3) amivantamab-vmjw Sensitive : A1 Adv Ther - 2wk	amivantamab-vmjw Sensitive: A1 - Approval Adv Ther - 2 weeks amivantamab-vmjw Sensitive : A1 Adv Ther - 2 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks (New C3) ceritinib Sensitive : A1 Cancer Manag Res - 2wk	ceritinib Sensitive: A1 - Approval Cancer Manag Res - 2 weeks ceritinib Sensitive : A1 Cancer Manag Res - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks (New C3) futibatinib Sensitive : A1 N Engl J Med - 2wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks futibatinib Sensitive : A1 N Engl J Med - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks (New C3) futibatinib Sensitive : A1 N Engl J Med - 2wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 2 weeks futibatinib Sensitive : A1 N Engl J Med - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) nivolumab + ipilimumab Sensitive : A1 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks (New A1) trastuzumab + tucatinib Sensitive : A1 FDA - 2wk	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks trastuzumab + tucatinib Sensitive : A1 FDA - 2 weeks - (New A1)
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks (New D) osimertinib Sensitive : C1 Cancer Lett - 2wk	osimertinib Sensitive: C1 - Off-label Cancer Lett - 2 weeks osimertinib Sensitive : C1 Cancer Lett - 2 weeks - (New D)
PD-L1 expression	Biliary Tract Cancer	PD-L1 expression	Biliary Tract Cancer	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C1 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks pyrotinib + dalpiciclib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) regorafenib Sensitive : C2 ASCO-GI 2023 - 2wk	regorafenib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks regorafenib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) toripalimab Sensitive : C2 ASCO-GI 2023 - 2wk	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks toripalimab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
POLD1 mutation	Solid Tumor	POLD1 mutation	Solid Tumor	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) toripalimab Sensitive : C2 ASCO-GI 2023 - 2wk	toripalimab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks toripalimab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2wk	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks camrelizumab + rivoceranib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C2 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C2 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) bevacizumab Sensitive : C2 ASCO-GI 2023 - 2wk	bevacizumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks bevacizumab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C2 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2wk	Her-VAXX Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks Her-VAXX Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) AB011 Sensitive : C2 ASCO-GI 2023 - 2wk	AB011 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks AB011 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 2wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) CMG901 Sensitive : C2 ASCO-GI 2023 - 2wk	CMG901 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks CMG901 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Cholangiocarcinoma	MDM2 amplification	Cholangiocarcinoma	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Biliary Tract Cancer	MDM2 amplification	Biliary Tract Cancer	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 2wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) panitumumab Sensitive : C3 ASCO-GI 2023 - 2wk	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks panitumumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks (New C3) erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2wk	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive	Colorectal Cancer	BRAF wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AB011 Sensitive : C3 ASCO-GI 2023 - 2wk	AB011 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AB011 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Solid Tumor	PD-L1 expression	Solid Tumor	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks durvalumab + tremelimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib + APL-502 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib + APL-502 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + TMB-H	Solid Tumor	MSI-H/dMMR + TMB-H	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2wk	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) regorafenib Resistant : C3 ASCO-GI 2023 - 2wk	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks regorafenib Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2wk	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 2wk	olaparib + durvalumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks olaparib + durvalumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	CAPRIN-1 expression	Gastroesophageal Junction Adenocarcinoma	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression	Gastric Cancer	CAPRIN-1 expression	Gastric Cancer	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab + TRK-950 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab + TRK-950 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + KMT2D mutation	Solid Tumor	MSI-H/dMMR + KMT2D mutation	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2wk	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L	Colorectal Cancer	THBS2-L	Colorectal Cancer	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C3 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Ampulla of Vater Carcinoma	MDM2 amplification	Ampulla of Vater Carcinoma	BI 907828 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C3 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R	Pancreatic Ductal Adenocarcinoma	KRAS G12R	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) FOLFIRINOX Sensitive : C3 ASCO-GI 2023 - 2wk	FOLFIRINOX Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks FOLFIRINOX Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R	Pancreatic Ductal Adenocarcinoma	KRAS G12R	Pancreatic Ductal Adenocarcinoma	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) irinotecan Sensitive : C3 ASCO-GI 2023 - 2wk	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks irinotecan Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	CHEK2 mutation	Pancreatic Ductal Adenocarcinoma	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) irinotecan Sensitive : C3 ASCO-GI 2023 - 2wk	irinotecan Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks irinotecan Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C3 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation	Colorectal Cancer	MSI-H/dMMR + RAS mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 2 weeks (New C4) pembrolizumab Sensitive : C4 BMJ Case Rep - 2wk	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 2 weeks pembrolizumab Sensitive : C4 BMJ Case Rep - 2 weeks - (New C4)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks (New C4) palbociclib Sensitive : C4 Onco Targets Ther - 2wk	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks palbociclib Sensitive : C4 Onco Targets Ther - 2 weeks - (New C4)
CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies The Oncologist - 2 weeks (New C4) capmatinib Sensitive : C4 The Oncologist - 2wk	capmatinib Sensitive: C4 – Case Studies The Oncologist - 2 weeks capmatinib Sensitive : C4 The Oncologist - 2 weeks - (New C4)
EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks (New C4) osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2wk	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2 weeks - (New C4)
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
EGFR L860R	Lung Adenocarcinoma	EGFR L860R	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks (New D) osimertinib Sensitive : D Cancer Lett - 2wk	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks osimertinib Sensitive : D Cancer Lett - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) nivolumab Sensitive : D ASCO-GI 2023 - 2wk	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks nivolumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) pembrolizumab Sensitive : D ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) Bv-AVE-PC Sensitive : A2 NCCN - 3wk	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks Bv-AVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) AEPA-CAPDAC Sensitive : A2 NCCN - 3wk	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks AEPA-CAPDAC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CVbP Sensitive : A2 NCCN - 3wk	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks CVbP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CHOP Sensitive : A2 NCCN - 3wk	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks CHOP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OEPA Sensitive : A2 NCCN - 3wk	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks OEPA Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) ABVE-PC Sensitive : A2 NCCN - 3wk	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks ABVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CFI-402257 Sensitive: B - Late Trials Treadwell Therap Press Release - 3 weeks (New B) CFI-402257 Sensitive : B Treadwell Therap Press Release - 3wk	CFI-402257 Sensitive: B - Late Trials Treadwell Therap Press Release - 3 weeks CFI-402257 Sensitive : B Treadwell Therap Press Release - 3 weeks - (New B)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks (New B) RG6026 Sensitive : B Roche Press Release - 3wk	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks RG6026 Sensitive : B Roche Press Release - 3 weeks - (New B)
MYCL expression	Non Small Cell Lung Cancer	MYCL expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks (New B) MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3wk	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3 weeks - (New B)
MYCN expression	Non Small Cell Lung Cancer	MYCN expression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks (New B) MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3wk	MRT-2359 Sensitive: B - Late Trials Monte Rosa Therap Press Release - 3 weeks MRT-2359 Sensitive : B Monte Rosa Therap Press Release - 3 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval Breast Cancer - 3 weeks (New C3) trastuzumab + pertuzumab Sensitive : A1 Breast Cancer - 3wk	trastuzumab + pertuzumab Sensitive: A1 - Approval Breast Cancer - 3 weeks trastuzumab + pertuzumab Sensitive : A1 Breast Cancer - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks (New A1) mobocertinib Sensitive : A1 Takeda Press Release - 3wk	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks mobocertinib Sensitive : A1 Takeda Press Release - 3 weeks - (New A1)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval Ther Adv Med Oncol - 3 weeks (New C3) trastuzumab Sensitive : A1 Ther Adv Med Oncol - 3wk	trastuzumab Sensitive: A1 - Approval Ther Adv Med Oncol - 3 weeks trastuzumab Sensitive : A1 Ther Adv Med Oncol - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval J Clin Oncol - 3 weeks (New C3) pembrolizumab Sensitive : A1 J Clin Oncol - 3wk	pembrolizumab Sensitive: A1 - Approval J Clin Oncol - 3 weeks pembrolizumab Sensitive : A1 J Clin Oncol - 3 weeks - (New C3)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval Oncogene - 3 weeks (New C3) alpelisib Sensitive : A1 Oncogene - 3wk	alpelisib Sensitive: A1 - Approval Oncogene - 3 weeks alpelisib Sensitive : A1 Oncogene - 3 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks (New B) nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3wk	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	lapatinib Sensitive: A2 - Guideline Eur J Cancer - 3 weeks (New B) lapatinib Sensitive : A2 Eur J Cancer - 3wk	lapatinib Sensitive: A2 - Guideline Eur J Cancer - 3 weeks lapatinib Sensitive : A2 Eur J Cancer - 3 weeks - (New B)
HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials JCO Precis Oncol - 3 weeks (New C3) tipifarnib Sensitive : B JCO Precis Oncol - 3wk	tipifarnib Sensitive: B - Late Trials JCO Precis Oncol - 3 weeks tipifarnib Sensitive : B JCO Precis Oncol - 3 weeks - (New C3)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) vemurafenib Sensitive : C1 J Transl Med - 3wk	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks vemurafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) dabrafenib Sensitive : C1 J Transl Med - 3wk	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks dabrafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
PBRM1 mutation	Non Small Cell Lung Cancer	PBRM1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Front Genet - 3 weeks (New C3) Immunotherapy Resistant : C3 Front Genet - 3wk	Immunotherapy Resistant: C3 – Early Trials Front Genet - 3 weeks Immunotherapy Resistant : C3 Front Genet - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials BMC Med - 3 weeks (New C3) BPI-7711 Sensitive : C3 BMC Med - 3wk	BPI-7711 Sensitive: C3 – Early Trials BMC Med - 3 weeks BPI-7711 Sensitive : C3 BMC Med - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks (New C3) gefitinib + AB-329 Sensitive : C3 Cancer Med - 3wk	gefitinib + AB-329 Sensitive: C3 – Early Trials Cancer Med - 3 weeks gefitinib + AB-329 Sensitive : C3 Cancer Med - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks (New C3) osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3wk	osimertinib + MEDI9447 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks osimertinib + MEDI9447 Sensitive : C3 J Thorac Oncol - 3 weeks - (New C3)
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks (New C4) anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3wk	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3 weeks - (New C4)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1